ISABELLE LIEBSCHUTZ

About ISABELLE LIEBSCHUTZ

Isabelle Liebschutz is a French executive with deep expertise in pharmaceutical quality, regulatory affairs, and industrial compliance. She currently plays a key leadership role at CROSSJECT, the French medtech and specialty pharma company known for its needle-free ZENEO® auto-injector platform. Within the company, she serves as Director of Quality and Regulatory Affairs and as a member of the Executive Board. CROSSJECT also identifies her as the company’s qualified person/pharmacist, underlining her responsibility for quality oversight and regulatory governance across the organization. Liebschutz joined CROSSJECT in 2013 after more than 17 years in the pharmaceutical industry. Her career began at Laboratoires Fournier, where she spent five years on the Formulation and Development team. That experience gave her a strong foundation in pharmaceutical development, process understanding, and product quality requirements. She then spent seven years as a Quality Assurance Manager, overseeing transdermal devices, outsourced products, and quality systems on behalf of Laboratoires Fournier and later Solvay, with responsibilities spanning both European and U.S. markets. This period gave her broad exposure to international quality standards and regulatory expectations in a highly controlled environment. From 2008 to 2013, she served as Responsible Pharmacist at a contract manufacturing organization specialized in the industrialization and manufacturing of pharmaceutical products and medical devices. In that role, she strengthened her operational command of GMP requirements, release processes, traceability, and regulatory compliance. At CROSSJECT, her expertise supports the company’s development and registration milestones, particularly for programs intended for emergency medicine delivery through the ZENEO® platform. Her reappointment to the Executive Board in 2025 reflects the board’s confidence in her ability to lead the company through complex quality and regulatory challenges, especially as CROSSJECT advances key U.S. filing and registration steps.